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Abstract
Background: Overactivated microglia that cluster at neuritic plaques constantly release neurotoxins, which actively 
contribute to progressive neurodegeneration in Alzheimer's disease (AD). Therefore, attenuating microglial clustering 
can reduce focal neuroinflammation at neuritic plaques. Previously, we identified CCL5 and CCL2 as prominent 
chemokines that mediate the chemotaxis of microglia toward beta-amyloid (Aβ)aggregates. Although transforming 
growth factor-β1 (TGF-β1) has been shown to down-regulate the expression of chemokines in activated microglia, 
whether TGF-β1 can reduce the chemotaxis of microglia toward neuritic plaques in AD remains unclear.
Methods: In the present study, we investigated the effects of TGF-β1 on Aβ-induced chemotactic migration of BV-2 
microglia using time-lapse recording, transwell assay, real-time PCR, ELISA, and western blotting.
Results: The cell tracing results suggest that the morphological characteristics and migratory patterns of BV-2 
microglia resemble those of microglia in slice cultures. Using this model system, we discovered that TGF-β1 reduces 
Aβ-induced BV-2 microglial clustering in a dose-dependent manner. Chemotactic migration of these microglial cells 
toward Aβ aggregates was significantly attenuated by TGF-β1. However, these microglia remained actively moving 
without any reduction in migration speed. Pharmacological blockade of TGF-β1 receptor I (ALK5) by SB431542 
treatment reduced the inhibitory effects of TGF-β1 on Aβ-induced BV-2 microglial clustering, while preventing TGF-β1-
mediated cellular events, including SMAD2 phosphorylation and CCL5 down-regulation.
Conclusions: Our results suggest that TGF-β1 reduces Aβ-induced microglial chemotaxis via the SMAD2 pathway. The 
down-regulation of CCL5 by TGF-β1 at least partially contributes to the clustering of microglia at Aβ aggregates. The 
attenuating effects of SB431542 upon TGF-β1-suppressed microglial clustering may be mediated by restoration of 
CCL5 to normal levels. TGF-β1 may ameliorate microglia-mediated neuroinflammation in AD by preventing activated 
microglial clustering at neuritic plaques.
Background
Alzheimer's disease (AD) is associated with chronic
inflammation induced by overactivated microglia in the
central nervous system [1,2]. Overactivated microglia
surrounding neuritic plaques persistently release pro-
inflammatory mediators and reactive oxygen species,
thereby causing a vicious cycle of neuroinflammation and
neuronal degeneration [2-6]. The phagocytic role of
microglia that cluster around neuritic plaques remains
controversial because only minimal amounts of Aβ are
internalized by these cells in AD brains [7,8]. It is plausi-
ble that preventing the clustering of microglia at neuritic
plaques may reduce microglial overactivation and neuro-
degeneration.
Elevated levels of multiple chemokines and their recep-
tors in AD brains suggest that there is chemotactic migra-
tion of microglia toward Aβ plaques [9,10]. For example,
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the accumulation of microglia is enhanced by the overex-
pression of CCL2 in transgenic mice overexpressing
human amyloid precursor protein (hAPP) [11]; con-
versely, knockout of the CCL2 receptor diminishes
microglial accumulation in these mice [12]. In a prior
study, we identified CCL5 as a prominent chemokine that
mediates Aβ-induced clustering of BV-2 microglia [13].
These results suggest that chemokines actively partici-
pate in microglial chemotaxis toward neuritic plaques
and that elevated chemokine levels can recruit more
microglia toward these plaques.
Transforming growth factor-β1 (TGF-β1) has multiple
roles including modulating inflammation and neuronal
survival [14,15]. Upon binding of TGF-β1, type I and type
II TGF-β1 receptors activate SMAD2/3 [15]. TGF-β1 sig-
naling has been shown to play a pivotal role in down-reg-
ulating chemokines and chemokine receptors [16,17]. In
addition, down-regulation of TGF-β type II receptors in
neurons has been shown to promote the pathogenesis of
AD [14]. The regulatory role of TGF-β1 in AD pathogen-
esis, therefore, has been intensively examined by over-
expressing TGF-β1 or blocking the TGF-β-SMAD signal-
ing pathway [14,18,19] Wyss-Coray et al. showed that
overexpression of TGF-β1 prominently reduces plaque
formation and Aβ accumulation in hAPP mice [19]. Their
data also suggest that TGF-β1 enhances Aβ clearance by
BV-2 microglia, and, thus, the TGF-β1 pathway may
serve as a potential therapeutic target for AD [20]. In fact,
a perplexing result in the Wyss-Coray et al. report was
that, despite the reduction in plaque burden, activated
microglia did not appear to cluster around the plaques.
Therefore, the role of TGF-β1-SMAD signaling in AD
pathogenesis warrants further investigation.
The purpose of this study was to explore the role of
TGF-β1 in the chemotaxis of microglia toward Aβ using a
cellular approach. Our data suggested that TGF-β1 pre-
vents clustering of microglial cells around Aβ aggregates
by attenuating their migration toward neuritic plaques
through activation of the SMAD pathway and down-reg-
ulation of CCL5.
Methods
Preparation of aggregated and fibrillar β-amyloid
Aggregated Aβ25-35 was prepared at 4°C for 60 h and
were incubated at 37°C for 48 h [21]. Fibrillar Aβ1-42 and
FAM-Aβ1-42 were prepared as described [22]. Briefly, Aβ
peptides were dissolved in hexafluoroisopropanol
(Sigma-Aldrich, St. Louis, MO) to a concentration of 1
mM and aliquoted. After hexafluoroisopropanol was
removed, an Aβ aliquot was suspended in 10 mM HCl at
a concentration of 100 μM for 24 h at 37°C to form fibril-
lar Aβ.
BV-2 microglia culture
BV-2 cells were maintained in a humidified incubator
with 5% CO2 at 37°C. The culture medium was Dul-
becco's modified Eagle medium (DMEM, Gibco, Grand
Island, NY) supplemented with 5% low-endotoxin fetal
bovine serum (FBS, HyClone, Logan, UT), 100 units/ml
penicillin (Sigma-Aldrich), 100 μg/ml streptomycin
(Gibco), and 2 mM L-glutamine (Sigma-Aldrich).
Primary microglial cultures
Primary rat microglia was prepared as described [23].
Briefly, cortices of neonates at postnatal day one were dis-
sociated by papain and endonuclease followed by tritura-
tion. Mixed glial cultures were grown in low-endotoxin
medium with 10% fetal bovine serum after 24 h. After 14
days in vitro, microglia were separated from astrocytes by
gentle agitation.
Quantification of microglial clusters
BV-2 cells (5 × 104) were incubated with 3 μM fibrillar
Aβ1-42 or 10 μM aggregated Aβ25-35 for 24 h. TGF-β1
pretreatment was carried out 1 h before the addition of
Aβ. The distribution of clustered BV-2 cells was photo-
graphed as described [13]. A cluster of BV-2 cells was
defined as more than 10 cells stacked upon each other
surrounding aggregated Aβ. The experiments were
repeated at least three times.
Transwell assay
BV-2 cells and rat primary microglia (3.5 × 104) were
seeded in the inserts of transwells (Corning Costar Corp.,
Cambridge, MA, USA, 8.0 μm pore size) with or without
a TGF-β1 pretreatment for 30 min. The transwell assay
was performed as described [24]. The insert was trans-
ferred into a well containing serum-free DMEM with or
without Aβ in the lower compartment and incubated for
2 h in 5% CO2 at 37°C. Microglia that migrated to the
lower surface were stained with Hoechst 33258. Images
w e r e  t a k e n  f r o m  f o u r  r a n d o m  f i e l d s  w i t h  a  f l o r e s c e n t
microscope at 4× magnification. The number of micro-
glia on the lower surface of the insert was quantified. The
experiments were repeated at least three times.
Cell tracing and migration speed analysis
BV-2 cells (2 × 105) were seeded in a 35-mm plate and
incubated for 2 h. The migration of BV-2 treated with
aggregated FAM-labeled Aβ was recorded by time-lapse
recording as described [13]. The migration trace of BV-2
cells was recorded over an area of 400 × 368 μm2 between
frames 1 and 105. The coordinates of cell tracings were
graphed using Microsoft Excel. More than 10 randomly
selected cells from each experiment were tracked for four
periods: 0-2.5 h, 5-7.5 h, 10-12.5 h, and 15-17.5 h after theHuang et al. Journal of Neuroinflammation 2010, 7:28
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addition of Aβ. The cell track between two frames was
processed by the "track point" function of MetaMorph.
The migration speed was calculated by dividing the dis-
tance traveled by the cell over two frames by 3 min. Cells
stuck in the cluster were excluded from speed analysis.
Speeds derived from tracking a single cell over 50 frames
during a 2.5-h period were averaged. Speed distributions
of more than 10 cells from each experiment were ana-
lyzed. The migration speeds of cells were ranked into
three classes: 0-1.5 μm/min, 1.5-3 μm/min, and greater
than 3 μm/min. The average speeds of more than 30 cells
were calculated from at least three independent record-
ings.
Western blotting analysis
BV-2 cells were starved in serum-free medium for 4 h
before treatments. BV-2 cells were treated with TGF-β1
for the indicated durations, and cell lysates were then pre-
pared. The inhibitory effects of SB431542 on TGF-β1-
induced SMAD2 phosphorylation were examined by
SB431542 pretreatment for 30 min followed by TGF-β1
treatment for 30 min. Briefly, cell lysates collected at the
indicated time points were subjected to western blot
assay using antibodies against phospho-SMAD2, SMAD
2 (1:500), and monoclonal mouse actin antibody (1:2,000,
Sigma-Aldrich) individually, followed by either goat anti-
rabbit antibody (1:1,000, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) or goat anti-mouse antibody (1:1,000,
Upstate, Virginia, USA) for 1 h. The immune complex
was detected by Western Lightning Western Blot Chemi-
luminescence Reagent (PerkinElmer Life Sciences, Bos-
ton, MA). The experiments were repeated three times.
Real-time PCR
Real-time PCR amplification of cDNA prepared from
BV-2 cells after different treatments was performed using
the SYBR Green qPCR Master Mix method (Fermentas
Life Sciences, Burlington, Ontario, Canada) in a Corbett
Rotor-Gene 3000 system. The levels of CCL2 and CCL5
mRNA were quantified. The experiments were repeated
at least three times. The primer sequences of each gene
were as follows: GAPDH sense primer: 5'-CCTTCCGT-
GTTCCTACCC, antisense primer: 5'-AAGTCGCAG-
GAGACAACC;  CCL5  sense primer: 5'-TGCCCA
CGTCAAGGAGTATTT; antisense primer: 5'-TCTCTG-
GGTTGGCACACACTT;  CCL2  sense primer: 5'-
TGAATGTGAAGTTGACCCGT; and antisense primer:
5'-AAGGCATCACAGTCCGAGTC.
Quantification of chemokines by ELISA
Medium from BV-2 cells after different treatments was
collected for ELISA. Concentrations of CCL2 and CCL5
in the medium were assayed using a mouse CCL2/JE and
CCL5/RANTES DuoSet ELISA Development kit (R&D
Systems, Minneapolis, MN, USA) following the manufac-
turer's instructions and detected by an ELISA reader
(Labsystems Multiskan RC, Helsinki, Finland). The
experiments were repeated at least three times.
Statistical analysis
Data was analyzed by one-way analysis of variance
(ANOVA), followed by the Tukey's HSD (honestly signifi-
cant difference) test, using Statistical Analysis System
software (SAS, SAS Institute Inc., Cary, NC). A p value
less than 0.05 was considered statistically significant and
marked with an asterisk in the figures.
Results
Aβ-induced chemotactic migration of BV-2 microglia is 
attenuated by TGF-β1
The chemotactic migration of microglia toward Aβ
aggregates has been previously suggested [11-13]. Since
TGF-β1 down-regulates the expression of chemokines in
microglia, whether TGF-β1 regulates Aβ-induced clus-
tering of BV-2 microglia cells was examined. Our results
indicate that TGF-β1 dramatically diminishes clustering
of BV-2 microglia at aggregated Aβ25-35 (Fig. 1A). The
suppressive effect of TGF-β1 on Aβ-induced microglial
clusters was significant at 5, 10, and 20 ng/ml (Fig. 1B).
The clusters of BV-2 cells induced by both aggregated
Aβ25-35 and fibrillar Aβ1-42 were reduced after TGF-β1
treatment by more than 50% (Fig. 1C).
The transwell assay was then used to examine whether
TGF-β1 could attenuate the chemotaxis of BV-2 micro-
glia. TGF-β1 (10 ng/ml) effectively reduced the number
of BV-2 microglia migrating toward the lower chamber
that contained either aggregated Aβ25-35 or fibrillar
Aβ1-42 (Fig. 2A, B). Consistently, primary microglia
migrated to the lower chamber containing fibrillar Aβ1-
42 (Fig. 2C). The suppressive effect of TGF-β1 on the Aβ-
induced migration of primary microglia in the transwell
assay was significant at 1, 5, and 10 ng/ml.
To further characterize the effects of TGF-β1 on the
migratory behavior of Aβ-treated microglia, time-lapse
recording of BV-2 cells was performed (Fig. 3). Cytoplas-
mic extensions of BV-2 cells protruded forward in the
direction of movement with a long tail. This movement
resembled activated microglia in brain slices induced by
forebrain stab lesions [25]. The real-time migration of
control, TGF-β1-, and Aβ-treated BV-2 cells with and
without TGF-β1 is presented as in Additional file 1, Addi-
tional file 2, Additional file 3 and Additional file 4. After
354 min, the addition of aggregated Aβ caused two to
three BV-2 cells to cluster. After 648 min, the size of the
BV-2 clusters increased (Fig. 3A, B). In contrast, TGF-β1
attenuated the formation of Aβ-induced BV-2 clusters
(Fig. 3C, D). Figure 3B and 3D show the marked areas in
Figure 3A and 3C, illustrating the movement of BV-2 cellsHuang et al. Journal of Neuroinflammation 2010, 7:28
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at a higher magnification 366 and 420 min following the
addition of Aβ. During this time, the clustered BV-2 cells
surrounded the aggregated Aβ (Fig. 3B). In the TGF-β1-
pretreated group, cells #1-3, located in the vicinity of
aggregated Aβ, migrated away from the Aβ aggregates
(Fig. 3D). These results suggest that the driving force of
chemotaxis toward Aβ aggregates is reduced in the TGF-
β1-pretreated group.
A representative cell tracing shows that control, TGF-
β1-treated, and TGF-β1-pretreated Aβ-treated cells
migrate randomly for long distances without any defined
direction (Fig. 4A). However, Aβ-treated BV-2 cells
migrated toward Aβ aggregates. Six hours after the addi-
tion of Aβ, more than 50% of traced microglia clustered at
Aβ aggregates (Fig. 4B). Once these cells formed clusters,
they rarely migrated away from the Aβ aggregates. In the
Figure 1 TGF-β1 attenuated Aβ-induced microglial clustering in a dose-dependent manner. BV-2 cells were treated with TGF-β1 for 1 h, fol-
lowed by 10 μM aggregated Aβ25-35 for 24 h. Images of control, TGF-β1-, and Aβ-treated BV-2 cells, with and without TGF-β1 treatment, were taken 
with a phase-contrast microscope (A). Images were taken from four random fields with a phase-contrast microscope to quantify the number of mi-
croglial clusters (B). BV-2 cells were treated with TGF-β1 at different doses for 1 h, followed by aggregated Aβ25-35 or fibrillar Aβ1-42 for 24 h. The 
number of BV-2 clusters was counted. Bars represent the mean ± SEM. * = p < 0.05. Scale bar: 50 μm.Huang et al. Journal of Neuroinflammation 2010, 7:28
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TGF-β1-pretreated Aβ-treated group, less than 14% of
traced microglia migrated toward the Aβ aggregates.
Conversely, TGF-β1-pretreated cells encountered Aβ
aggregates, and then subsequently migrated away from
these aggregates. These data support the conclusions
drawn from the transwell assay that TGF-β1 attenuates
the chemotaxis of microglia toward Aβ.
To address whether TGF-β1 reduces the migration
speed of microglia, the speeds of four groups were ana-
lyzed (Fig. 4C). The speeds of BV-2 microglia greatly
decreased when interacting with other cells, which also
resembled those of activated microglia induced by fore-
brain stab lesions [25]. More than 50% of both control
and TGF-β1-only cells migrated between 1.5-3 μm/min.
Figure 2 TGF-β1 suppressed Aβ-induced microglial chemotaxis in the transwell assay. BV-2 cells were seeded in the inserts of transwells with 
or without 10 ng/ml TGF-β1. The inserts were transferred to transwells containing 10 μM Aβ25-35 and incubated for 2 h. Images of control, TGF-β1-, 
and Aβ-treated BV-2 cells, with and without TGF-β1 treatment, were taken from four random fields at 4× magnification (A). The cell number in the 
lower chamber of the insert was quantified (B). Primary microglia were seeded in inserts of transwells with or without TGF-β1 at different concentra-
tions and incubated for 30 minutes. The cells in the lower chamber of the insert were quantified (C). Bars represent the mean ± SEM. * = p < 0.05.Huang et al. Journal of Neuroinflammation 2010, 7:28
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However, the number of cells migrating at speeds greater
than 3 μm/min increased, while the number of cells
migrating at speeds between 0-1.5 μm/min decreased in
the Aβ-treated group. The average migration speed of
microglia in the control and TGF-β1 groups was approxi-
mately 2 μm/min. The average speed of the Aβ-treated
group did not change with time. Surprisingly, the migra-
tion speeds of the TGF-β1-pretreated Aβ-treated group
increased significantly between 15-17.5 h following the
a d d i t i o n  o f  A β .  T h e r e f o r e ,  w e  m a y  c o n c l u d e  t h a t  t h e
attenuation of BV-2 clustering at Aβ by TGF-β1 was not a
result of reduction in migration speed of microglia.
TGF-β1 type I receptor mediates the suppressive effects of 
TGF-β1 on Aβ-induced microglia clustering
TGF-β1-SMAD2/3 signaling has been shown to mediate
down-regulation of cytokines and chemokines [26,27].
SB431542, an inhibitor of the TGF-β1 type I receptor
(ALK5), is commonly used to block SMAD2/3 phospho-
rylation induced by TGF-β1 [28-31]. To examine whether
t h e  T G F - β 1  t y p e  I  r e c e p t o r  m e d i a t e s  t h e  i n h i b i t o r y
effects of TGF-β1 on Aβ-induced microglial cluster for-
mation, SB431542 was used in the assay of microglial
clustering. The inhibitory effect of TGF-β1 on Aβ-
induced microglial clustering was significantly attenuated
by SB431542 (Fig. 5A). Concurrently, SB431542 effec-
tively suppressed TGF-β1-induced SMAD2 phosphoryla-
tion in BV-2 microglia (Fig. 5B). The relative intensities of
phospho-SMAD2/SMAD2/3 suggest that SB431542
effectively suppressed TGF-β1-induced SMAD2 phos-
phorylation in BV-2 microglia. Consistent results were
observed by using actin and total SMAD2/3 to normalize
levels of phospho-SMAD2. Quantitative analysis of west-
ern blots of triplicate experiments showed that the level
of SMAD2 phosphorylation induced by TGF-β1 was sig-
nificantly down-regulated by SB431542 (Fig. 5C). Our
Figure 3 The differential migratory behavior of Aβ-treated microglia in the absence and presence of TGF-β1. BV-2 cells were pretreated with 
10 ng/ml TGF-β1 for 1 h, followed by FAM-labeled aggregated Aβ. Continuous cellular movements were recorded by time-lapse microscopy from 
more than three independent experiments. The images (top to bottom) indicate frames recorded at the indicated times, respectively (A, C). BV-2 cells 
formed clusters at Aβ aggregates between 354 min and 942 min after the addition of Aβ (A). The addition of TGF-β1 attenuated BV-2 clustering at Aβ 
aggregates (C). Cell movement of the marked areas in A and C was monitored between 366 and 420 min at a higher magnification (B, D). Instead of 
clustering toward the Aβ aggregates, cells # 1-3 migrated away from Aβ without stalling. Scale bar: 100 μm.Huang et al. Journal of Neuroinflammation 2010, 7:28
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data suggest that inhibition of SMAD2 phosphorylation,
which is a downstream effector of ALK5, can mediate the
i n h i b i t o r y  e f f e c t s  o f  T G F - β 1  o n  A β - i n d u c e d  m i c r o g l i a
clustering.
Our previous study indicated that both CCL5 and
CCL2 mediate the chemotactic migration of microglia
toward Aβ aggregates [13]. Whether TGF-β1 down-regu-
lates CCL5 and CCL2 was then investigated. Levels of
both CCL5 mRNA and secreted CCL5 in the medium
Figure 4 Cell tracings and speed analysis of Aβ-treated microglia in the absence and presence of TGF-β1. The migratory tracks of control, TGF-
β1-, and Aβ-treated BV-2 cells, with and without TGF-β1 were labeled in different colors (A). The migratory direction of BV-2 cells are represented by 
the vectors linking the start and end points (B). Speed distributions were analyzed during 0-2.5, 5-7.5, 10-12.5, and 15-17.5 h after the addition of Aβ 
aggregates (C). Black bars represent the percentage of cells with a speed between 0-1.5 μm/min. Light gray bars represent the percentage of cells 
with a speed between 1.5-3 μm/min. Dark gray bars represent the percentage of cells with a speed greater than 3 μm/min. Average speeds were 
calculated by averaging the migration speed during the entire recording period (D). Bars represent the mean ± SEM. Comparisons marked with as-
terisks are significant different. At least 10 cells from each independent time-lapse recording were pooled for speed distribution and average speed 
analysis. * = p < 0.05.Huang et al. Journal of Neuroinflammation 2010, 7:28
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were significantly decreased by TGF-β1 pretreatment in
the Aβ-treated group (Fig. 5D, E). However, there were no
significant changes in the levels of CCL2 mRNA and
secreted CCL2 in the medium of the TGF-β1 pretreated
A β - t r e a t e d  g r o u p .  F u r t h e r m o r e ,  b l o c k a d e  o f  A L K 5  b y
SB431542 completely reversed the down-regulation of
CCL5 mRNA in the TGF-β1 pretreated Aβ-treated group
(Fig. 5F). Our data suggest that binding of TGF-β1 acti-
vates ALK5 and leads to phosphorylation of SMAD2.
Phosphorylated SMAD2 may down-regulate CCL5 and
attenuate chemotaxis of microglia toward Aβ aggregates.
Discussion
It has been suggested that overactivated microglia sur-
rounding neuritic plaques produce proinflammatory
cytokines and chemokines that recruit more neurotoxic
microglia and lead to further neuroinflammation [1,3-6].
Therefore, attenuation of overactivated microglia at neu-
ritic plaques may be a therapeutic strategy for AD. In the
present study, we used a time-lapse recording approach
to examine the effects of TGF-β1 on Aβ-induced micro-
glial clustering. Our data suggests that TGF-β1 signifi-
cantly inhibits microglial chemotaxis toward Aβ.
Phosphorylated SMAD2 and down-regulation of CCL5
were at least partially involved in mediating the effects of
TGF-β1. These results suggest that TGF-β1 may have
therapeutic potential for AD by preventing excessive
microglial clustering at neuritic plaques, since microglial
overactivation at neuritic plaques actively contributes to
neurodegeneration [32].
Although microglia have been shown to be recruited
and activated by nearby plaques [33], the trajectory of
microglial movement in vivo has not been examined
because of the difficulty in monitoring microglial cluster-
ing at neuritic plaques. Our study provides, for the first
time, real-time tracing data of microglial migration
toward Aβ aggregates. BV-2 cells have been widely used
to study microglial migration induced by alpha-synuclein
and cannabinoid [34,35]. The migratory behavior of BV-2
cells is similar to that of primary microglia [36]. Further-
more, the morphology and behavior of migrating BV-2
cells in our study resembled that of microglia in brain
Figure 5 Phosphorylation of SMAD2 and down-regulation of CCL5 are involved in the attenuation of Aβ-induced microglial clustering by 
TGF-β1. BV-2 cells were treated with SB431542 for 1 h prior to the addition of TGF-β1. Subsequently, BV-2 cells were incubated with Aβ. The number 
of clusters was quantified (A). Representative western blot analysis of phospho-SMAD2 after the addition of TGF-β1 for different durations and the 
inhibitory effect of SB431542 on SMAD2 phosphorylation (B). The relative intensities of phospho-SMAD2 compared to control were analyzed (C). The 
levels of CCL2 and CCL5 mRNA in BV-2 cells after different treatments were compared by real-time PCR (D). ELISA kits were used to measure the levels 
of CCL2 and CCL5 in the medium of BV-2 cells after different treatments (E). The effects of SB431542 on the down-regulation of CCL5 mRNA levels 
after TGF-β1 treatment were analyzed (F). Bars represent the mean ± SEM. All of the data were collected from three independent experiments. * = p 
< 0.05.Huang et al. Journal of Neuroinflammation 2010, 7:28
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slices [25]. Although the clustering of BV-2 microglia
around Aβ aggregates in vitro may not accurately mimic
microglia around neuritic plaques in AD, our approach
provides a tractable system for the study of molecular
mechanisms of TGF-β1 attenuation of microglia chemot-
axis toward neuritic plaques.
TGF-β1 overexpression has been shown to prominently
reduce plaque formation and Aβ accumulation in hAPP/
TGF-β1 double transgenic mice [19]. It is suggested that
TGF-β1 enhances the uptake of Aβ by microglia. How-
ever, Town et al. showed that the blockade of TGF-β1-
SMAD2/3 signaling in peripheral macrophages reduces
Aβ deposits in hAPP mice, and they demonstrated that
such blockade enhances infiltration of macrophages into
the central nervous system [18]. Furthermore, it has been
shown that TGF-β1 knockout mice develop spontaneous
neurodegeneration [37,38]. Blockade of neuronal TGF-β1
signaling has been shown to reduce neuronal survival
rate and enhance amyloid deposition in AD mice [14].
These studies suggest that the function of the TGF-β1-
SMAD2/3 pathway is cell-type specific. Therefore, the
neuroprotective effects of TGF-β1 in AD may directly
promote neuronal survival as well as enhance Aβ uptake
and prevent the clustering of overactivated microglia at
senile plaques.
Phosphorylation of SMAD2/3, the downstream effec-
tor of ALK4, 5, and 7, has been shown to be responsible
for the transmission of TGF-β signaling in mammalian
cells [15]. Several studies have suggested that SMAD2/3
signaling mediates the down-regulation of chemokines
during inflammatory responses [26,27]. SB431542, a spe-
c i f i c  A L K 5  i n h i b i t o r ,  i s  c o m m o n l y  u s e d  t o  i n h i b i t
SMAD2/3 phosphorylation [39-41], and has been used to
attenuate the neuronal protective effects of TGF-β1 in
Aβ-injected rats [42]. A key finding in this study is the
inhibition of SB431542 on TGF-β1-suppressed microglia
clustering and its concurrent effects on inhibiting
SMAD2 phosphorylation and restoring CCL5 expression.
Based on the specificity of SB431542 for the TGF-β1-
SMAD2/3 pathway [39-41], a logical conclusion is that
TGF-β1 reduces microglial clustering and CCL5 expres-
sion by activating the ALK5-SMAD2 pathway. Due to the
lack of a SMAD2-specific inhibitor, it is impossible to
exclude SMAD3 or other effectors as responsible for the
inhibitory effects on microglial chemotaxis toward Aβ.
CCL5 can serve as a microglia activator and a chemokine
in dendritic cells [43]. Moreover, the deletion of the CCL5
gene significantly reduces glial activation induced by dif-
ferent stimuli, suggesting that CCL5 can activate micro-
glia [44]. Thus, down-regulation of CCL5 by TGF-β1 at
neuritic plaques may prevent sequential microglial clus-
tering and microglia activation.
Although numerous studies suggest that microglia sur-
rounding senile plaques express pro-inflammatory cytok-
ines, Colton et al. has shown that genes involved in tissue
repair are upregulated in microglia of AD patients and
AD mice [45]. Microglia can be beneficial as well as dele-
terious due to the various phenotypes of microglia under
different microenvironments in CNS [46]. For example,
the ligation of CD40-CD40L induces TNF-α production.
This proinflammatory phenotype is attenuated by TGF-
β1 and IL-10 [47]. Different types of stimuli will lead to
distinct microglial responses; therefore, the broad spec-
trum of microglial activation should be evaluated during
the development of therapeutic strategies of AD.
Conclusions
Taken together, our results suggest that TGF-β1 reduces
chemotaxis of microglia toward Aβ aggregates, and that
this effect at least partially involves down-regulation of
CCL5. CCL5 down-regulation via ALK5-SMAD2 signal-
ing may reduce neuroinflammation and neuronal damage
in AD. TGF-β1 should be further explored as a potential
target for the development of therapeutic strategies to
treat AD.
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